Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10731484 | 0.87 | AKR1C3 (0.62) | AKR1C3HDAC8PTGS1ALDH1A1LMNA | |
| SCHEMBL10839698 | 0.87 | AKR1C3 (0.62) | AKR1C3HDAC8PTGS1ALDH1A1LMNA | |
| SCHEMBL10825923 | 0.84 | AKR1C3 (0.68) | AKR1C3HDAC8PTGS1ALDH1A1LMNA | |
| SCHEMBL2625197 | 0.84 | BCL2 (0.61) | PTGS1ALDH1A1SMN1; SMN2ERCC5FEN1 | |
| SCHEMBL7427631 | 0.82 | CES2 (0.67) | SMN1; SMN2NPC1MEN1KMT2ARAB9A | |
| SCHEMBL12667381 | 0.82 | KMT2A (0.58) | ALDH1A1LMNASMN1; SMN2PARP10NPC1 | |
| SCHEMBL8767835 | 0.81 | AKR1C3 (0.64) | AKR1C3HDAC8PTGS1ALDH1A1LMNA | |
| SCHEMBL14519864 | 0.81 | LMNA (0.58) | ALDH1A1LMNASMN1; SMN2NPC1MEN1 | |
| SCHEMBL2350424 | 0.80 | AKR1C3 (0.72) | AKR1C3HDAC8PTGS1ALDH1A1LMNA | |
| SCHEMBL8248607 | 0.80 | ALDH1A1 (0.72) | AKR1C3HDAC8PTGS1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-20130295261-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8420145-B2 | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | AKR1C3 227/4885HDAC8 1467/4885PTGS1 3824/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | AKR1C3 3302/4885HDAC8 389/4885PTGS1 1886/4885 |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | TAS2R10, TAS2R41, TAS2R30 | AKR1C3 3307/4885HDAC8 3608/4885PTGS1 2194/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | AKR1C3 235/4885HDAC8 1164/4885PTGS1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.